Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.
Saved in:
| Title: | Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. |
|---|---|
| Authors: | Ryan C; Charles Institute of Dermatology, University College, Dublin, Ireland.; Institute of Dermatologists, Dublin, Ireland., Guenther L; Guenther Dermatology Research Centre, London, ON, Canada., Foley P; Skin Health Institute, Melbourne, VIC, Australia., Weisman J; Medical Dermatology Specialists, Atlanta, GA, USA., Burge RT; Eli Lilly and Company, Indianapolis, IN, USA.; University of Cincinnati, Cincinnati, OH, USA., Gallo G; Eli Lilly and Company, Indianapolis, IN, USA., See K; Eli Lilly and Company, Indianapolis, IN, USA., McKean-Matthews M; Syneos Health, Raleigh, NC, USA., Bertram CC; Eli Lilly and Company, Indianapolis, IN, USA., Merola JF; Harvard Medical School, Boston, MA, USA. |
| Source: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2022 Apr; Vol. 36 (4), pp. e277-e279. Date of Electronic Publication: 2021 Dec 04. |
| Publication Type: | Clinical Trial, Phase III; Letter; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1468-3083 |
|---|---|
| DOI: | 10.1111/jdv.17836 |
